This study documented a significant improvement in survival among patients with breast cancer without HER2 overexpression or amplification but with IHC scores of 1+ or 2+ and non-amplified results on ISH who were treated with trastuzumab deruxtecan [11]. Here, ERBB2 is linked to breast carcinoma.